

# Invasive mucinous adenocarcinoma misdiagnosed as pneumonia: A case report

YUPING YANG<sup>1</sup>, RONGFEI HUANG<sup>2</sup>, LIPING XIANG<sup>1</sup>, JUN ZENG<sup>1</sup>, WEI ZHAO<sup>3</sup> and NA HUANG<sup>1</sup>

Departments of <sup>1</sup>Pulmonary and Critical Care Medicine and <sup>2</sup>Pathology, The First Affiliated Hospital of Chengdu Medical College; <sup>3</sup>School of Laboratory Medicine, Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China

Received September 13, 2022; Accepted February 10, 2023

DOI: 10.3892/etm.2023.11867

**Abstract.** Common imaging findings of invasive mucinous adenocarcinoma (IMA) include consolidation of the lung parenchyma, nodules, and ground-glass changes. However, the IMA imaging findings in the present case included diffuse, patchy and blurry density shadows through both lungs. To the best of the authors' knowledge, this image pattern has rarely been reported. The patient provided his consent and authorized the publication of photographs featuring his likeness. The present study reported a patient was diagnosed with IMA via pathologic and genetic analyses. Following antibiotic treatment, the lesions in both sides became larger. Further examinations were completed and IMA was confirmed by biopsy pathohistological examination. Pathological specimens were negative for almost all driver genes mutations, except KRAS. The patients and family refused further treatment, including chemotherapy, radiotherapy and interventional chemotherapy and the patient was discharged from The First Affiliated Hospital of Chengdu Medical College. The present case report emphasized that IMA should be suspected when imaging studies show diffuse lesions throughout both lungs. When a patient does not respond to treatment, clinicians should consider alternative diagnoses.

## Introduction

According to global cancer statistics, lung cancer is the leading cause of cancer-related deaths worldwide (1). As a new category of non-small cell lung cancer (NSCLC) in 2015 according to World Health Organization classification, invasive mucinous adenocarcinoma (IMA) accounts for 2-5% of lung adenocarcinomas (2,3). Based on image diagnosis, IMA usually has abundant intracellular/extracellular mucus and invasive adenocarcinoma patterns. The typical computed tomography (CT) of IMA, includes consolidation, ground-glass opacity and nodules (2). Clinically, IMA is easily misdiagnosed as pneumonia (4,5).

The present study presented an IMA case, which manifested as diffuse, patchy and blurry density shadows throughout both sides. It emphasized that bronchioloalveolar carcinoma should be suspected when radiological manifestations show diffuse, patchy and blurry density shadows throughout all lobes. The present study was approved by the ethics committee review board of the First Affiliated Hospital of Chengdu Medical College (approval no. 2019CYFYIRB-BA-Jun13). The patient provided signed informed consent and authorized the publication of the images.

## Case presentation

A 45-year-old male complained of a cough with production of sputum without obvious cause for a year. He denied chest pain, fever, chest tightness, shortness of breath, hemoptysis, night sweats, palpitations, eyelid edema and extremity edema. He was treated at another hospital and diagnosed with 'pneumonia'. He was discharged from the hospital with symptom improvement after anti-infection treatment. Following discharge, he repeatedly coughed, with sputum production. For every episode, his symptoms were relieved after anti-infection treatment. However, the symptoms recurred and became worse after 2 days of treatment. Chest digital radiography (DR) showed diffuse, patchy and blurry density shadows throughout both lungs (Fig. 1A). He was transferred to the Departments of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, for further treatment.

His vital signs were within normal limits. Physical examination revealed coarse breath sounds and scattered wet rales

---

*Correspondence to:* Dr Wei Zhao, School of Laboratory Medicine, Chengdu Medical College, 783 Xindu Road, Chengdu, Sichuan 610500, P.R. China  
E-mail: zw198626520@126.com

Dr Na Huang, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, 783 Xindu Road, Chengdu, Sichuan 610500, P.R. China  
E-mail: huangna213@163.com

*Abbreviations:* IMA, invasive mucinous adenocarcinoma; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; DR, digital radiography; CT, computed tomography

*Key words:* invasive mucinous adenocarcinoma, misdiagnosis, pneumonia, antibiotic treatment




Figure 1. DR of the chest. (A) DR imaging before anti-infective treatment in The First Affiliated Hospital of Chengdu Medical College in March 4th, 2019. (B) DR of the Chest in The First Affiliated Hospital of Chengdu Medical College in March 22, 2019 after anti-infection treatment. Arrows indicates the patchy and flocculent fuzzy density shadows that are diffusely distributed in both lungs. DR, digital radiography.




Figure 2. CT scan of the chest. (A) CT and (B) enhanced CT of the chest. Arrows indicates the shadow in the upper lobe of the right and left lungs. CT, computed tomography.

in the bilateral lungs. Laboratory tests at admission included white blood cell count ( $0.42 \times 10^9/l$ ), percentage of lymphocytes (12.1%), and percentage of neutrophils (80.1%). His C-reactive protein level was 5.4 mg/l, and his erythrocyte sedimentation rate was 20 mm/h. T-SPOT for tuberculosis infection was positive, with 84 spots in panel A and 18 spots in panel B. A tumor marker test showed the following: Carcinoembryonic antigen, 48.15 ng/ml; carbohydrate antigen 19-9, >400.00 U/ml; carbohydrate antigen 153, 75.49 U/ml; carbohydrate antigen 242, >200.00 U/ml; cytokeratin 19-fragment, 5.19 ng/ml; and carbohydrate antigen 72-4, 70.33 U/ml. Renal function, electrolyte level, and blood coagulation function were in the normal ranges. Chest CT showed the following: i) Diffuse, patchy and blurry hyperdense shadows, nodular shadows

and patchy consolidation, which were more obvious in the right upper lobe and left lung; the image findings suggested a suspected infectious lesion, but other lesions could not be ruled out; ii) multiple lymph nodes with partial calcification in the mediastinum and the lungs; and iii) minor effusion in the left thoracic cavity and bilateral pleural thickening (Fig. 2A). Enhanced chest CT showed: i) diffuse, patchy and blurry hyperdense shadows and nodular shadows that were more obvious in the right upper lobe and left lung; enhancement of CT was not clear, the image findings suggested a suspected infectious lesion, but other lesions could not be ruled out; ii) multiple lymph nodes with partial calcification in the mediastinum and the lungs; and iii) minor effusion in the left thoracic cavity and bilateral pleural thickening (Fig. 2B).




Figure 3. Fiberoptic investigation. Fiberoptic bronchoscopy of (A) tracheal carina, (B) right upper lobe, (C) left main bronchus and (D) right main bronchus.




Figure 4. CT and pathology results. (A) CT guided percutaneous lung biopsy. Pathological images of (B) hematoxylin-eosin and (C) TTF-1 IHC staining (original magnification, x10; scale bars, 100 μm). CT, computed tomography; TTF-1, thyroid transcription factor 1; IHC, immunohistochemical.

Table I. Detection of genes mutations.

Gene	Mutation	Conclusion
EGFR	NO	KRAS G12C is the 'driver' gene in this case. Sotorasib and Adagrasib are recommended for treatment.
HER2	NO	
KRAS	G12C	
ALK	NO	
BRAF	NO	
PI3KA	NO	
L861Q	NO	
TRIM4	NO	
VAMP2	NO	
NRG1	NO	
CD74	NO	

The patient received empiric antimicrobial therapy following admission. Combined cefuroxime sodium (0.75 g/8 h, intravenous injection) and moxifloxacin hydrochloride (0.4 g/day, intravenous injection) were administered for anti-infection treatment. According to the results of chest CT and enhanced chest CT, it was possible to consider infectious lesion. At one week following anti-infective treatment, chest DR examination showed that the lesions were more advanced than before (Fig. 1B). The T-SPOT test was positive but with a small number of spots. The possibility of tuberculosis was low. The patient's tumor marker levels were significantly elevated. IMA could not be ruled out. Thus, fiberoptic bronchoscopy was performed and found no obvious morphological change (Fig. 3). The pathological examination suggested that the mucosal epithelium was undergoing chronic inflammatory changes with mucosal epithelial cell proliferation (data not shown). A case discussion in Departments of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College considered a tumor diagnosis according to the tumor marker and pathology results. A percutaneous lung puncture biopsy was performed (Fig. 4A). The collected samples were fixed in 10% neutral buffered formalin 24 h at room temperature and embedded in paraffin. Sections were cut at 5  $\mu$ m and hematoxylin-eosin and thyroid transcription factor 1 (TTF-1) immunohistochemical (IHC) staining (6) were performed following the manufacturer's protocols. The adenocarcinoma was diagnosed based on the pathological staining which were evaluated independently by two pathologists at the First Affiliated Hospital of Chengdu Medical College in a double-blinded manner (Fig. 4B and C). Pathological specimens were almost negative for all driver genes, except KRAS (Table I). However, there was no KRAS G12C molecular targeted drug in 2019 and the patients and family refused treatment, including chemotherapy, radiotherapy and interventional chemotherapy and the patient was discharged from the hospital.

## Discussion

IMA, formerly known as mucinous bronchioloalveolar carcinoma, is a special type lung adenocarcinoma. It is more common in women and not associated with smoking. Its

incidence has increased in recent decades (7). Its etiology and mechanism remain unclear, but the occurrence of IMA may be related to a variety of risk factors such as EGFR, KRAS and/or HER2 genes mutation (8-10). Its occurrence is associated with genetic factors, environmental factor and chronic inflammation. The pathological basis may be the invasive growth of cancer tissue derived from bronchioles or alveoli. When disseminated in the airway, the cancer cells cover the surface of the alveolar wall and grow along the alveolar wall (8). Recently, Kimura *et al* (11) reported a esophageal metastasis of IMA and combined with emerging data (12), suggests that IMA can progress into a more aggressive status.

Some patients with IMA are asymptomatic, while some have nonspecific respiratory symptoms, including coughing with sputum production, blood-tinged sputum, and dyspnea, and systemic symptoms including fever, fatigue and weight loss. Physical examination is usually unremarkable (4).

The diagnosis of IMA is challenging. Imaging findings can vary and be nonspecific, including consolidation of the lung parenchyma, nodules, honeycomb signs and ground-glass changes (13). However, common findings including irregular masses and absence of lung cancer signs. Mucus changes may manifest as consolidation that is difficult to differentiate from infectious pneumonia. It is easily misdiagnosed as pneumonia tuberculosis or pulmonary actinomycosis (14). IMA is difficult to diagnose not only because of its nonspecific clinical manifestations but also because of inflammation signs in imaging studies. The affected alveoli and normal alveoli are arranged in a mixed manner, which in this case manifested in the imaging study as diffuse and vague patchy shadows throughout both lungs. These findings are consistent with pneumonia-like changes; therefore, IMA can easily be misdiagnosed as pneumonia (4,15,16). The diffuse, patchy, and blurry shadows throughout both lungs are nonspecific and can be noted in various pulmonary infectious diseases such as pneumonia and tuberculosis. Differentiating IMA from other lung diseases depends mainly on pathological results. According to the literature, the case reported is relatively rare because diffuse and patchy shadows are unusual in patients with IMA. Most IMA cases manifest as patch consolidation in the lungs rather than diffuse and patchy shadows in the bilateral lungs. It was

learned from this case that diffuse patchy shadows may be signs of IMA.

As a subtype of lung adenocarcinoma, IMA has similar epidemiology with other subtypes. However, IMA has unique imaging characters, such as consolidation, ground-glass opacity and nodules (2). IMA is divided into two types by the shape of image, pneumonic and solid types. These types have a great difference in clinical outcome. Compared with pneumonia IMA, the isolated type usually has lower pathological stage with more satisfying outcome. The difference is probably due to the prevalence of the pulmonary type IMA (17,18). Reports have also found the disease free survival of pneumonic type patients is significantly worse and this type of patient was more prone to have cancer recurrence and/or metastasis after resection (17,19). In the present study, the IMA case had typical pneumonic characters. It predicted unfavorable survival of this patient, although the family refused to disclose the status of patient when this case was followed up.

According to previous reports, KRAS mutation is the most common 'driver' mutation in IMA, its incidence in IMA is significantly higher compared with other lung adenocarcinomas (20,21). By contrast, other targeted 'driver' mutations are rare in IMA patients, such as EGFR mutation, ALK gene rearrangement and BRAF V600E mutation (20,22,23). In addition, rare gene mutations, such as HER2, BRAF and PI3KA mutations and rare gene fusion, such as TRIM4-BRAF, VAMP2-NRG1 and CD74-NRG1 fusion, are observed in IMA patients with alteration-negative K-RAS (24). In the present study, the sequencing data showed the present case has KRAS gene alteration without EGFR, ALK and BRAF mutation, as well as rare genes, such as, TRIM4, VAMP2, NRG1 and CD74. In 2021-2022, Sotorasib (25) and Adagrasib (26) were approved for KRAS G12C-mutated non-small cell lung cancer (NSCLC). Thus, there are more molecular therapeutic choices for this type of IMA.

Immune checkpoint inhibitors (ICI) are widely used to treat patients with NSCLC (27). Nakagomi *et al* (28) reported that expression of PD-L1 in  $\geq 1\%$  of cells is observed in only 6.1% of IMAs, but in 59.7% of conventional adenocarcinomas. In agreement, Xu *et al* (29) found only 9.7% (3/31) of patients with IMA revealed positive PD-L1 expression. The aforementioned evidence suggests that ICI treatment rarely benefits IMA patients.

Compared with untreated IMA patients, the overall survival rate of IMA patients receiving conventional chemotherapy does not improve (14). Early IMA patients can benefit from surgery and postoperative chemotherapy. At present, there are no effective drugs for the treatment of advanced pulmonary IMA (6,14).

Clinically, the clinical manifestations of IMA are atypical, and the imaging findings vary. The diagnosis is often missed, and misdiagnosis is common. These issues may delay treatment. The diagnosis of IMA can be confirmed by a pathological examination. Therefore, in clinical practice, when patients with large lung consolidation do not respond to regular anti-infection treatment and the lesion progresses, IMA should be considered. Early pathological examination should be performed to rule out IMA, so as not to delay disease treatment. For early staged IMA, surgery and postoperative chemotherapy is recommended. Selected molecular-targeted is a superior choice base on the result of sequencing.

## Acknowledgements

Not applicable.

## Funding

The present study was supported by Natural Science Foundation of Sichuan Province (grant no. 2022NSFSC0725).

## Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

## Authors' contributions

YY and RH performed data curation. LX and JZ utilised software. Hematoxylin-eosin and immunohistochemical staining was performed by RH. WZ and NH conceived and designed the study. WZ provided supervision. NH and WZ wrote the original draft. NH analyzed and interpreted data. WZ and NH confirm the authenticity of all the raw data. All authors revised the manuscript. All authors read and approved the final manuscript.

## Ethics approval and consent to participate

Clinical data collection was approved by the Medical Ethics Committee of The First Affiliated Hospital of Chengdu Medical College (approval no. 2019CYFYIRB-BA-Jun13). Informed written consent for participation in the study or use of the medical data was obtained from the patient.

## Patient consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 71: 209-249, 2021.
2. Sheng A, Zhou P, Ye Y, Sun K and Yang Z: Diagnostic efficacy of CT radiomic features in pulmonary invasive mucinous adenocarcinoma. *Scanning* 2022: 5314225, 2022.
3. Xu X, Shen W, Wang D, Li N, Huang Z, Sheng J, Rucker AJ, Mao W, Xu H and Cheng G: Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma. *Transl Lung Cancer Res* 11: 420-431, 2022.
4. Butt YM and Allen TC: The demise of the term bronchioloalveolar carcinoma. *Arch Pathol Lab Med* 139: 981-983, 2015.
5. Read WL, Page NC, Tierney RM, Piccirillo JF and Govindan R: The epidemiology of bronchioloalveolar carcinoma over the past two decades: Analysis of the SEER database. *Lung Cancer* 45: 137-142, 2004.
6. Oktay E, Oflazoglu U, Varol Y, Tanriverdi O, Mermur N, Arda HU, Demir L, Keskin O, Ahmadi T, Somali I, *et al*: The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma. *J Cancer Res Ther* 16: 737-744, 2020.

7. Gardiner N, Jogai S and Wallis A: The revised lung adenocarcinoma classification-an imaging guide. *J Thorac Dis* 6: 537-546, 2014.
8. Moser L, Kegler K, Precht C and Zanolari P: Bronchioalveolar carcinoma in an adult alpaca (*Vicugna pacos*). *BMC Vet Res* 15: 139, 2019.
9. He Y, Huang H, Xu M, Fu Z, Zhang X, Chen X and Guo W: The effect of afatinib in a pretreated patient with invasive mucinous adenocarcinoma of the lung harboring HER2 YVMA insertion: A case report. *Transl Cancer Res* 11: 1819-1823, 2022.
10. Chi K, Sun W, Yang X, Wu J, Wang H, Liu X, Mao L, Zhou L, Huang X and Lin D: A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in KRAS-mutant invasive non-mucinous adenocarcinoma. *Thorac Cancer* 13: 1050-1058, 2022.
11. Kimura S, Onishi I and Kobayashi M: A rare case of esophageal metastasis of invasive mucinous adenocarcinoma of the lung. *ACG Case Rep J* 9: e00857, 2022.
12. Chen X, Zhao Y, Wang D, Lin Y, Hou J, Xu X, Wu J, Zhong L, Zhou Y, Shen J, *et al*: The HNF4 $\alpha$ -BC200-FMR1-positive feedback loop promotes growth and metastasis in invasive mucinous lung adenocarcinoma. *Cancer Res* 81: 5904-5918, 2021.
13. Zhang X, Qiao W, Kang Z, Pan C, Chen Y, Li K, Shen W and Zhang L: CT features of stage IA invasive mucinous adenocarcinoma of the lung and establishment of a prediction model. *Int J Gen Med* 15: 5455-5463, 2022.
14. Zhu D, Zhang Q, Rui Z and Xu S: Pulmonary invasive mucinous adenocarcinoma mimicking pulmonary actinomycosis. *BMC Pulm Med* 22: 181, 2022.
15. Mir E, Sareen R, Kulshreshtha R and Shah A: Bronchioloalveolar cell carcinoma presenting as a 'non-resolving consolidation' for two years. *Pneumonol Alergol Pol* 83: 208-211, 2015.
16. Narahari NK, Uppin SG, Kapoor A, Stalin BJ and Paramjyothi GK: Invasive mucinous adenocarcinoma of the lung in a 19-year-old female. *Asian Cardiovasc Thorac Ann* 26: 635-639, 2018.
17. Nie K, Nie W, Zhang YX and Yu H: Comparing clinicopathological features and prognosis of primary pulmonary invasive mucinous adenocarcinoma based on computed tomography findings. *Cancer Imaging* 19: 47, 2019.
18. Kim DH, Bae SY, Na KJ, Park S, Park IK, Kang CH and Kim YT: Radiological and clinical features of screening-detected pulmonary invasive mucinous adenocarcinoma. *Interact Cardiovasc Thorac Surg* 34: 229-235, 2022.
19. Wang T, Yang Y, Liu X, Deng J, Wu J, Hou L, Wu C, She Y, Sun X, Xie D and Chen C: Primary invasive mucinous adenocarcinoma of the lung: prognostic value of CT imaging features combined with clinical factors. *Korean J Radiol* 22: 652-662, 2021.
20. Horiguchi T, Yanagi S, Tomita M, Maeda R, Uto K, Shigekusa T, Tsubouchi H, Matsumoto N and Nakazato M: A case of bilateral invasive mucinous adenocarcinoma of the lung with severe productive cough and dyspnea successfully treated with palliative lung lobectomy. *Respir Med Case Rep* 32: 101368, 2021.
21. Kadota K, Yeh YC, D'Angelo SP, Moreira AL, Kuk D, Sima CS, Riely GJ, Arcila ME, Kris MG, Rusch VW, *et al*: Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: Invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. *Am J Surg Pathol* 38: 1118-1127, 2014.
22. Boland JM, Maleszewski JJ, Wampfler JA, Voss JS, Kipp BR, Yang P and Yi ES: Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma-a clinicopathological and molecular genetic study with survival analysis. *Hum Pathol* 71: 8-19, 2018.
23. Cha YJ, Kim HR, Lee HJ, Cho BC and Shim HS: Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. *Lung Cancer* 102: 82-88, 2016.
24. Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Hoang Ho Q, Onozato M, Phi Le L, Heist RS and Iafrate AJ: Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. *J Thorac Oncol* 10: 1156-1162, 2015.
25. Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, Bi Y, Liu J, Rahman A, Wearne E, *et al*: FDA approval summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. *Clin Cancer Res* 28: 1482-1486, 2022.
26. Frontline promise for Adagrasib-Pembrolizumab combination. *Cancer Discov* 13: OF2, 2022.
27. Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascoux C, Couraud S, Veillon R, *et al*: Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol* 30: 1321-1328, 2019.
28. Nakagomi T, Goto T, Hirotsu Y, Shikata D, Yokoyama Y, Higuchi R, Otake S, Amemiya K, Oyama T, Mochizuki H and Omata M: Genomic characteristics of invasive mucinous adenocarcinomas of the lung and potential therapeutic targets of B7-H3. *Cancers* 10: 2018.
29. Xu X, Li N, Wang D, Chen W and Fan Y: Clinical relevance of PD-L1 expression and CD8<sup>+</sup> T cells' infiltration in patients with lung invasive mucinous adenocarcinoma. *Front Oncol* 11: 683432, 2021.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.